Author of

• 10583

  +

  P1.06 - Poster Session 1 - Prognostic and Predictive Biomarkers (ID 161)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10584

    +

    P1.06-001 - HDL-Cholesterol is Reduced in Advanced Stage Lung Cancer Patients With Weight Loss (ID 122)

    09:30 - 09:30  |  Author(s): A. Ozgun
    • Abstract

    Background
    Lipids play roles in several biological functions such as cell growth, division, and membrane stabilization in normal and cancer cells. There has been also interest in the relation of serum lipid levels and cancer in various studies. Epidemiological studies have demonstrated that high total cholesterol level is associated decreased cancer incidence. On time of diagnosis, HDL-cholesterol levels are reduced in lung cancer patients. We investigated the relation between lipid profile and weight loss in advanced stage lung cancer patients.

    Methods
    Forty-eight advanced stage lung cancer patients and 20 healthy subjects were included in the study. SCLC patients had extensive stage disease and NSCLC patients were stage IIIB and IV. All of study patients and control subjects were smoker and non-obese. Serum lipid profile, total protein, albumin, erythrocyte sedimentation rate (ESR) and clinical data were recorded.

    Results
    Lower HDL-cholesterol levels detected in advanced stage lung cancer patients. Serum total cholesterol, total protein, and albumin levels were also lower in cancer patients than controls. Serum LDL-cholesterol measurements were not different between patients and healthy subjects. However, ESR is higher in patients than controls. Twenty-four patients had weight loss. Total cholesterol, HDL-cholesterol, and LDL-cholesterol levels were lower in the patients with than without weight loss. However, total cholesterol, HDL-cholesterol, and LDL-cholesterol levels were not different between lung cancer patients without weight loss and control subjects. In lung cancer patients, serum HDL-cholesterol level was correlated with inversely ESR; directly with serum albumin level.

    Conclusion
    Although the weak association between HDL-cholesterol and cancer has been reported and the effect of HDL-cholesterol in carcinogenesis has been discussed, we not found difference in lipid profiles of lung cancer patients without weight loss. We consider that the reduction of lipid levels may be related to cancer cachexia. Moreover, serum albumin level and ESR, indirectly markers of inflammation, were correlated with HDL-cholesterol. It is known that inflammation reduce HDL-cholesterol. The cause of coincidence between reducing HDL-cholesterol and cancer may be inflammatory process. Further studies that investigate the clinical signification of reduced HDL-cholesterol and other lipids are necessary.

• 12441

  +

  P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers (ID 178)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12442

    +

    P3.06-001 - Serum Nesfatin-1 Level As A Biomarker In Non-Small Cell Lung Cancer (ID 79)

    09:30 - 09:30  |  Author(s): A. Ozgun
    • Abstract

    Background
    Nesfatin-1 is an anorexigenic neuropeptide. We have previously reported that serum nesfatin-1 level is decreased in lung cancer patients. In this study, we aimed to investigate possible effects of serum nesfatin-1 level in survival and chemotherapy response of non-small cell lung cancer patients.

    Methods
    Twenty-eight non-small cell lung cancer patients were included in this study. Data were obtained from clinical records and our previously study about nesfatin-1. The patients were divided into two groups according to high nesfatin-1 level or low. Survival data were compared between these groups. Moreover, serum nesfatin-1 levels were investigated in chemotherapy responder and non-responder patients.

    Results
    Three of patients received supportive care alone. Twenty-five patients were treated with platinum-based doublet chemotherapy. In chemotherapy non-responder patients, serum nesfatin-1 level was more lower than in the patients achieved clinical benefit (0.38 ng/ml ±0.12 ng/ml vs 0.55 ng/ml ±0.21 ng/ml; p:0.044). Patients with low nesfatin-1 level had shorter overall survival (OS), but it is not statistically significant (median OS 7.3 months vs 13.8 months, respectively; p: 0.829). Serum nesfatin-1 levels were not also different in between patients survived more than 12 months and not (0.62 ng/ml ±0.22 ng/ml vs 0.46 ng/ml ±0.19 ng/ml; p:0.077).

    Conclusion
    This preliminary study suggests that serum nesfatin-1 level is not prognostic factor in non-small cell lung cancer, but may be a predictive marker for chemotherapy response.